Deconvolution and Selective Control of Specific Biological Activities with Partially Acylated and Mixed SCFA-derivatized Monosaccharide-SCFA Hybrid Molecules

Value Proposition: This invention solves two problems inherent with the use of Short Chain Fatty Acid (SCFA)-monosaccharide hybrid molecules to modulate cellular activity. The first problem is the toxicity of former versions of these compounds. The current invention uses structure activity relationships as it has been discovered to either enhance or avoid toxicity (depending on the intended application). A second problem is that these compounds have a diverse set of biological activities and the current invention allows specific activities to be deconvoluted and selectively controlled; as a consequence better control can be gained over the biological responses elicited by these compounds. Two such applications described herein are control of stem cell differentiation and reduced invasiveness of cancer cells such as metastatic breast cancer cells.

Technical Details: This invention comprises fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

Looking for Partners: The compounds of the invention can be developed and commercialized as valuable targets for the development of carbohydrate based vaccine for cancer, influenza or HIV on the concept of glycoengineering and immunology. Additional compounds of the invention are applicable in the study of glycosylation of nuclear or cytosolic proteins, which contribute towards the design of drugs or vaccines for deadly disease like diabetes, or Parkinsons or Alzheimer's disease.

Patent Status: Granted US Patents 8,916,544 and 9,067,960

Category(s):